What are the microvascular and macrovascular complications of type 2 diabetes and how should they be managed?

Type 2 Diabetes Complications: Microvascular and Macrovascular Disease

Type 2 diabetes causes both microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular complications (cardiovascular disease, stroke, peripheral artery disease), with intensive glycemic control reducing microvascular disease by 25% and multifactorial risk management being essential to prevent cardiovascular events, which remain the leading cause of death in these patients. 1

Microvascular Complications

Diabetic Retinopathy

• Intensive glycemic control (achieving A1C ~7.0%) reduces retinopathy development and progression by approximately 25% compared to conventional treatment 1
• The relationship between glucose control and retinopathy risk is continuous and log-linear, extending into the normal A1C range with no threshold 1
• All patients require comprehensive dilated eye examinations annually by an ophthalmologist or optometrist experienced in diabetic retinopathy 2
• Anti-VEGF therapy has become the primary treatment for diabetic macular edema, typically requiring near-monthly intravitreal injections during the first year 3
• Blood pressure control and fenofibrate therapy (in patients with dyslipidemia) can slow retinopathy progression 3

Diabetic Kidney Disease (DKD)

• DKD is defined as persistent albuminuria (UACR >30 mg/g) or eGFR <60 mL/min/1.73 m² for at least 3 months, affecting approximately 40% of patients with type 2 diabetes 4
• Target blood pressure should be <130/80 mmHg in patients with diabetes and CKD stages 1-4 2
• ACE inhibitors or ARBs are first-line antihypertensive agents and should be used in combination with a diuretic 2
• SGLT2 inhibitors and GLP-1 receptor agonists are now recommended for kidney and cardiovascular protection in patients with DKD, independent of glycemic control needs 5, 4
• Annual screening for albuminuria and eGFR monitoring is essential for early detection 2

Diabetic Neuropathy

• Assessment for diabetic peripheral neuropathy should begin at diagnosis in type 2 diabetes and be performed at least annually 3
• Screening includes careful history and assessment of temperature or pinprick sensation (small fiber), vibration with 128-Hz tuning fork (large fiber), and annual 10-g monofilament testing 3
• Pregabalin, duloxetine, or gabapentin are recommended as initial pharmacologic treatments for neuropathic pain 3
• Gastroparesis should be suspected in patients with erratic glycemic control or upper gastrointestinal symptoms, with gastric emptying scintigraphy being the gold standard for diagnosis 3

Foot Complications

• Visual foot inspection should occur at each healthcare visit, with comprehensive foot examination (including Semmes-Weinstein monofilament testing and pedal pulse evaluation) performed annually 2
• High-risk patients (those with CKD, CVD, peripheral vascular disease, neuropathy, or diabetes duration >10 years) require referral to foot specialists for annual preventive care 2
• Daily self-inspection by patients is essential for early ulcer detection 2

Macrovascular Complications

Cardiovascular Disease

• Cardiovascular disease is the leading cause of death in people with diabetes, conferring a 2- to 4-fold increased risk 1
• While intensive glycemic control shows modest effects on macrovascular outcomes, the UKPDS demonstrated a 16% reduction in cardiovascular complications with intensive control (median A1C 7.0% vs 7.9%) 1
• Long-term follow-up from DCCT showed that early intensive glycemic control resulted in a 42% reduction in cardiovascular outcomes and 57% reduction in nonfatal MI, stroke, or CVD death after 9 years 1

Contemporary Cardiovascular Protection

• SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular and renal protection beyond glycemic control in high-risk patients with type 2 diabetes 5, 6
• Meta-analyses demonstrate that SGLT2 inhibitors reduce major cardiovascular events, with particular benefits for heart failure prevention 6
• These agents should be prescribed regardless of baseline A1C in patients with established cardiovascular disease or high cardiovascular risk 5

Dyslipidemia Management

• Target LDL-C should be <100 mg/dL in patients with diabetes and CKD stages 1-4, with <70 mg/dL as a therapeutic option for very high-risk patients 2
• Statin therapy should be initiated in patients with diabetes, CKD stages 1-4, and LDL-C >100 mg/dL 2
• Lipid-lowering therapy is cost-effective and significantly reduces cardiovascular events in patients with type 2 diabetes and CKD 2

Glycemic Targets and Management Strategy

A1C Goals

• The recommended A1C goal is <7% for most adults with diabetes, which balances microvascular risk reduction against hypoglycemia risk 1, 7
• More stringent goals (A1C 6-7%) may be appropriate for younger patients with long life expectancy and low hypoglycemia risk, particularly when using agents that don't cause hypoglycemia 7
• Less stringent goals may be necessary for patients with advanced complications, limited life expectancy, or high hypoglycemia risk 7

Multifactorial Approach

• The most effective strategy for preventing diabetes complications requires simultaneous management of glycemia, blood pressure, and lipids 8, 9
• The Steno-2 trial demonstrated that intensified multifactorial treatment of all modifiable risk factors significantly reduces peripheral vascular disease, ischemic events, and mortality in type 2 diabetes 10
• Early intervention after diagnosis provides long-lasting protective effects for both microvascular and macrovascular complications 11, 10

Critical Management Principles

Timing of Intervention

• Intensive therapy targeting glycemia and all cardiovascular risk factors should be initiated as soon after diagnosis as possible and maintained throughout life 10
• The duration of glycemic burden is a strong predictor of adverse outcomes, emphasizing the importance of early detection and treatment 12
• Type 2 diabetes frequently goes undiagnosed for years, during which patients remain at increased risk for developing complications 12, 13

Hypoglycemia Risk

• The major danger of intensive glycemic control is hypoglycemia, which was threefold higher in intensive treatment groups in the DCCT 11
• Recent trials (ACCORD, ADVANCE, VADT) demonstrated that lowering glycemic targets to near-normal levels does not further reduce cardiovascular events in individuals with longstanding type 2 diabetes and that hypoglycemia must be avoided in those with ischemic heart disease 10
• Weight gain is another adverse consequence of intensive insulin therapy that requires monitoring 11

Screening and Monitoring

• Self-monitoring of blood glucose should be performed at least 3 times daily in patients on multiple insulin injections (before meals and bedtime) 2
• HbA1c should be measured at least twice yearly in stable patients meeting goals, and approximately every 3 months in patients whose therapy has changed or who are not reaching goals 2
• Orthostatic blood pressure should be measured due to frequent autonomic neuropathy in diabetes and CKD 2